Trends in statin prescription prevalence, initiation, and dosing: Hong Kong, 2004–2015
Graphical abstract
Introduction
Statins are effective for primary and secondary prevention of cardiovascular disease [1,2]. In China, cardiovascular disease is the top cause of death [3], while in Hong Kong, heart diseases and cerebrovascular diseases together comprised 1 in 5 of all registered deaths in 2016 [4]. However, scant data are available on the trends in statin prescribing in Hong Kong.
The potential pharmacokinetic differences in Asian populations frequently necessitate a lower statin dose to achieve a comparable cholesterol reduction, as compared with Western populations [5]. In clinical trials [6,7], high-intensity statins caused an increased frequency of adverse effects versus lower intensities. Even moderate doses of simvastatin (40 mg/day) resulted in higher rates of myopathy in Chinese patients in the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial [8], which led to the new regulatory authority recommendations that the lowest dose of simvastatin should be used in Chinese patients [9].
There is also controversy as to whether high-intensity statins provide additional benefits in Asians. In an observational study of 14 866 Japanese patients who underwent their first coronary revascularization [10], the incidence of major adverse cardiovascular events, did not differ between patients prescribed standard statins and “strong” statins. Similarly, 1355 Chinese patients hospitalized for acute coronary syndrome, were randomized to receive a moderate-intensity statin or a high-intensity [11]. After two years of follow-up, there was no statistically significant difference between the two treatment groups. These results suggest that there may not be further clinical benefits to high-intensity statin therapy in most Asians.
Previous local studies show that low- or moderate-intensity statins are commonly prescribed rather than high-intensity statins [[12], [13], [14]]. In light of the evolution of clinical practice guidelines and statin safety concerns, whether there have been changes over time in statin prevalence and initiation has not been investigated in Hong Kong. The objectives of this study were to characterize statin prescription prevalence, statin treatment initiation rates, statin prescription dosing and the cardiovascular prevention status (primary or secondary) of statin users, in a cohort of Hong Kong patients who received a lipid test, between 2004 and 2015.
Section snippets
Data source
We used the data of patients accessing health services within the Hong Kong Hospital Authority: the statutory body that manages all publicly funded hospitals and ambulatory clinics in Hong Kong [15]. The Hospital Authority currently delivers primary, secondary, and tertiary care to the 7.3 million residents of Hong Kong through services at 42 public hospitals, 47 specialist clinics, and 73 general outpatient clinics. Electronic health records, including demographics, inpatient and outpatient
Patient characteristics
A total of 145,875 patients who underwent at least one lipid test between January 2004 and March 2014 were identified. After analyzing their prescription records, 40.2% of adult patients received at least one statin prescription during the observation period, and the majority were classified as primary prevention (Table 1). Most patients (77%) had a recorded lipid test prior to initiating a statin. There were slightly more males than females in the cohort and most patients were aged
Discussion
To our knowledge, this is the first study to report statin prescription prevalence, initiation, and dosing trends in Hong Kong. In 2015, the statin prescription prevalence was nearly five times greater than in 2004, while the statin prescription initiation rate doubled during the 12-year study period. There were also changes in statin drug choices and dosages. The most significant finding is that increases in statin prescribing have been driven by greater use of low- and moderate-intensity
Conflicts of interest
Esther W. Chan has received research funding from The Hong Kong Research Grants Council, The Research Fund Secretariat of the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, Narcotics Division of the Security Bureau of The Government of the Hong Kong Special Administrative Region, Bristol-Myers Squibb, Pfizer, Bayer and Janssen, a Division of Johnson & Johnson, for work unrelated to this study.
Ian C.K. Wong has received research funding from The Hong
Author contributions
Joseph E. Blais, Conceptualization, Data curation, Formal analysis, Visualization, Writing - original draft.
Esther W. Chan, Conceptualization, Supervision, Data curation, Writing - review & editing.
Sharon W.Y. Law, Formal analysis, Writing - review & editing.
Michael T. Mok, Methodology, Writing - review & editing.
Duo Huang, Writing - review & editing.
Ian C.K. Wong, Writing - review & editing.
Chung-Wah Siu, Conceptualization, Supervision.
Acknowledgements
We would like to thank Mr Jiaxi Zhao for his suggestions regarding data analysis.
References (41)
- et al.
China cardiovascular diseases report 2015: a summary
J. Geriatr. Cardiol.
(2017) - et al.
The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: results of the CHILLAS trial
Atherosclerosis
(2014) - et al.
STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease
Clin. Therapeut.
(2001) - et al.
Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour
Health Pol.
(2012) - et al.
Primary prevention with statins in the elderly
J. Am. Coll. Cardiol.
(2018) - et al.
Statins for the primary prevention of cardiovascular disease
Cochrane Database Syst. Rev.
(2013) - et al.
Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials
BMJ
(2005) Major causes of death [Internet]
(2016)- et al.
Racial differences in the cholesterol-lowering effect of statin
J. Atherosclerosis Thromb.
(2017) - et al.
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
N. Engl. J. Med.
(2005)
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
J. Am. Med. Assoc.
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
Eur. Heart J.
Singapore: new recommendations for simvastatin use in Asians based on findings from the HPS2-THRIVE study [Internet]
Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization: perspectives from the CREDO-Kyoto Registry Cohort-2
Circ. J.
Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong
Adv. Ther.
The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre
Hong Kong Med. J.
How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong?
BMC Cardiovasc. Disord.
Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation
J. Am. Med. Assoc.
Cardiovascular outcomes associated with use of clarithromycin: population based study
BMJ
Cited by (23)
Trends and determinants of prevalence, awareness, treatment and control of dyslipidaemia in canton of Geneva, 2005–2019: Potent statins are underused
2023, International Journal of Cardiology: Cardiovascular Risk and PreventionTen-Year Evolution of Statin Eligibility and Use in a Population-Based Cohort
2023, American Journal of CardiologyCitation Excerpt :Cardiovascular risk assessment is based on 2 major prediction models, namely the Systemic Coronary Risk Evaluation (SCORE) from the European Society of Cardiology (ESC)3,4 and the Pooled Cohort Equations (PCEs) from the American Heart Association (AHA) and the American College of Cardiology (ACC).2,5,6 Recent studies assessing the evolution of statin use reported an increase in the prescription of statins, although high-intensity statins were infrequently prescribed.7–13 However, some studies showed suboptimal dyslipidemia management14,15 but were based on a limited follow-up period or had a cross-sectional design.16–18
Trends in the Utilization of Lipid-Lowering Medications in Australia: An Analysis of National Pharmacy Claims Data
2022, Current Problems in CardiologyCitation Excerpt :We detected the highest prevalence of statins’ prescriptions in people aged 61-80 years, which is consistent with an Australian study assessing statin's prescribing patterns among older (aged >65 years) people21 and data from other developed countries.24,29,30 Other studies have demonstrated that incidence of statins is increasing in elderly populations,20,29 but our study, involving general adult population, demonstrated a 2-trend pattern; a decrease between 2014 and 2016, and an increase from 2017-2019. Although we cannot fully explain why the trend was bi-directional, it is believed that many patients fail to achieve their target LDL-C when using low or moderate statins, and recent changes in clinical guidelines that recommend initiation with a high-intensity statin in people who have very high absolute risk of CVD,5 may have been responsible.
Trends in lipid-modifying agent use in 83 countries
2021, AtherosclerosisCitation Excerpt :While in India growth in statin prescriptions and a large proportion of combination lipid-modifying agent product use was reported between 2006 and 2010 [27]. In East Asia, increased use of statins has been described in Hong Kong and Taiwan [28,29]. Taken together, the global trends in increased use of lipid-modifying agents continued over the past decade, but appear to have weakened since 2013.